Naples-Tokyo axis for novel generation of trispecific anti tumor antibodies

CEINGE signed a research agreement with CHIOME BIOSCIENCE Inc, a Japanese company based in Tokyo specialized in the production of antibodies and their derivatives capable of enhancing the immune response against cancer cells. CHIOME will be engaged with the team of Claudia De Lorenzo, professor at the Federico II University of Naples and Principal Investigator at CEINGE.

The collaborative project between Chiome and Ceinge will be focused on testing the effects of combinations of human immunomodulatory antibodies with the tribodies (bi specific or tri specific antibodies) constructs developed by Chiome and previously validated as effective antitumor T cell engager agents in vitro and in vivo.

The goal is the identification of the most effective combinations of antibodies in activating T cells against cancer cells for the generation of novel tribodies endowed with an increased potency.

The research project is based on a previous collaboration of CEINGE with the Keires company, which resulted in a patent of which CEINGE is a licensee. CHIOME also invested their patent in the project.

«We are very happy to have reached a research agreement with an international company, listed on the Tokyo stock exchange, such as CHIOME BIOSCIENCE», says Dr. Mariano Giustino, CEO and general manager of CEINGE.

«This agreement demonstrates the firm determination and the ability of CEINGE to translate the scientific skills of its scientists into applications that are potentially useful for human health», declares the Scientific Director, Prof. Roberto Di Lauro.